24 results
8-K
EX-1.1
ba8549
14 Feb 24
Other Events
4:11pm
8-K
EX-99.1
aou 8auhz
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.2
hpmb6 yeqxsq
13 Feb 24
Results of Operations and Financial Condition
4:10pm
S-3ASR
EX-4.3
7fj25
13 Feb 24
Automatic shelf registration
4:04pm
8-K
EX-2.1
ruik3v9yg
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
424B3
p2y38w4h0e d2
28 Aug 23
Prospectus supplement
9:10am
S-4/A
tgqyled
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
S-4
b3trbf1 fz
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
8-K
EX-10.1
3f3p t0khjwdx0phr
26 Apr 21
Immunome Announces $27 Million Private Placement
6:05am
10-K
olrwtmwqlr
25 Mar 21
Annual report
5:01pm
10-K
EX-10.27
7d56i5m xjwom
25 Mar 21
Annual report
5:01pm
424B4
vctkxsl7 p0t46ydi
5 Oct 20
Prospectus supplement with pricing info
5:10pm
S-1/A
ivk4qc
24 Sep 20
IPO registration (amended)
7:18am